Echocardiogram News and Research

RSS

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.

17 Mar 2011

Cancer patients' willingness to undergo tests bodes well for future of personalized medicine

Cancer patients are willing to undergo many tests to receive advanced experimental treatment in clinical trials, according to a new study by Mayo Clinic, Scottsdale Healthcare and the Translational Genomics Research Institute.

4 Mar 2011

Geron's hESC derived GRNCM1 halts remodeling process and preserves cardiac function in acute heart damage

Geron Corporation today announced preclinical study data showing positive effects of GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells (hESCs), in a small animal model of acute heart damage. Administering GRNCM1 by injection into the heart resulted in greater resistance to induced arrhythmias, halted adverse cardiac remodeling and preserved mechanical function compared to controls.

2 Mar 2011

New Rush clinic brings trained clinicians to care for patients with pulmonary hypertension

Cardiologists and pulmonologists at Rush University Medical Center have teamed up to provide a new and better approach to treating patients with pulmonary hypertension, a disease affecting the heart and lungs. The new Rush Pulmonary Hypertension Clinic brings together a multidisciplinary team of clinicians with specialized training to care for patients with this very complex disease.

16 Feb 2011

Mysteries of the hibernating heart

Hibernating, it turns out, is much more complicated than one might think.

8 Feb 2011

Ultrasound practice accreditation is now available in Fetal Echocardiography: AUSM

The American Institute of Ultrasound in Medicine announced today that ultrasound practice accreditation is now available in Fetal Echocardiography. The program sets the standard for care in fetal echocardiography and builds on the development of AIUM guidelines aimed at fostering its safe and effective use.

20 Jan 2011

Heart failure patients admitted to general wards fare poorly: Study

The latest research shows that patients with heart failure are twice as likely to die if they are admitted to a general hospital ward rather than one specializing in cardiology. Heart failure kills nearly a quarter of a million people in England and Wales every year and about 900,000 people in the UK have the condition that means the heart is weakened and cannot pump blood efficiently. Symptoms include fatigue, breathlessness and swollen ankles, and it can lead to premature death.

18 Jan 2011

Heart failure patients admitted to general wards twice as likely to die

Heart failure patients admitted to general wards are twice as likely to die as those admitted to cardiology wards, shows a national audit of the treatment of the condition, published online in the journal Heart.

18 Jan 2011

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension for use in stress echocardiography.

14 Dec 2010

Beaumont Hospital announces opening of new Ernst Cardiovascular Center

Beaumont Hospitals' world renowned heart center has expanded and enhanced its services with the Oct. 18 opening of the new Ernst Cardiovascular Center at Beaumont Hospital, Royal Oak.

21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

Terason and HEARTS Program seek to prevent SCA

The Terason t3000 CV Ultrasound is the ultrasound system of choice for The HEARTS Program a project of Memorial Hermann and UT Southwestern Hospitals. Houston Early Age Risk Testing and Screening (HEARTS) program, is a study designed to detect any abnormal heart conditions that can cause the heart to arrest.

13 Oct 2010

Center for Prenatal Pediatrics: A comprehensive care center for women and children

NewYork-Presbyterian Hospital/Columbia University Medical Center today announced the opening of The Carmen and John Thain Center for Prenatal Pediatrics. The new unit will provide high-risk pregnant women and their babies the most comprehensive care currently available, all in one location.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

TAVI procedure effective in patients unsuitable for surgical valve replacement: Study

One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

23 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

Athersys second-quarter revenues increase to $1.9 million

Athersys, Inc. today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010